CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 938 enrolled
Drug / intervention
Norethindrone Acetate/Ethinyl Estradiol 24 Days +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00932321
NCT00932321Phase 3Completed

Open Label, Randomized, Comparator-Controlled Study of the Contraceptive Efficacy of Norethindrone Acetate (NA) and Ethinyl Estradiol (EE)

Warner Chilcott·interventional·Posted Jul 3, 2009·Updated Apr 22, 2013

In Brief

A Phase 3 clinical trial evaluating Norethindrone Acetate/Ethinyl Estradiol 24 Days and Norethindrone Acetate /Ethinyl Estradiol 21 Days for Prevention of Pregnancy. Completed, enrolled 938 participants across 34 sites.

Detailed Summary

This is a comparative study. The primary objective of the study is to assess the efficacy of a low dose oral contraceptive in the prevention of pregnancy. The secondary objectives are to assess the incidence of intracyclic bleeding of norethindrone acetate/ethinyl estradiol (NETA/EE) administered for 24 days and NETA/EE administered for 21 days; and to assess the safety and tolerability of the product.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--

Timeline

Phase 3CompletedFinished
200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJul 3, 2009
Enrollment StartJan 1, 2004
Primary CompletionNov 1, 2004
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 17.0 years ago

Interventions

Norethindrone Acetate/Ethinyl Estradiol 24 Daysdrug

One tablet per day for 24 days of each 28 day cycle followed by 4 placebo tablets

Norethindrone Acetate /Ethinyl Estradiol 21 Daysdrug

One tablet per day for 21 days of each 28 day cycle followed by 7 placebo tablets